Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy
We successfully developed LUAD organoids harboring Kras mutations and identified multiple potential therapeutic agents targeting these cells. Furthermore, we demonstrated the effectiveness of a DNMT inhibitor-based combination therapy, presenting a promising strategy for this challenging lung cancer subtype.
Authors
- Julhash Uddin Kazi (ORCID: https://orcid.org/0000-0002-0719-5336)
- Juliane Albrecht (ORCID: https://orcid.org/0009-0004-4316-1581)
- Reinhilde Jacobs (ORCID: https://orcid.org/0000-0002-3461-0363)
- Hans Brunnström (ORCID: https://orcid.org/0000-0001-7402-138X)
- Wondossen Sime (ORCID: https://orcid.org/0000-0001-9518-2457)
- İsa Taş (ORCID: https://orcid.org/0000-0001-5306-8584)
- J. Aberg
- Samuel Andrés Barrientos
- Helena Persson (ORCID: https://orcid.org/0000-0002-5187-6446)
- Ramin Massoumi (ORCID: https://orcid.org/0000-0001-8875-6440)
Institutions
- Lund University (SE)
- Medicon Village (SE)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1186/s13046-025-03385-9
- Citations
- 4
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 3.75
Funders
- Cancerfonden
- Lunds Universitet
- Kungliga Fysiografiska Sällskapet i Lund